<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798612</url>
  </required_header>
  <id_info>
    <org_study_id>SJ-874</org_study_id>
    <nct_id>NCT04798612</nct_id>
  </id_info>
  <brief_title>Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression</brief_title>
  <acronym>IPOS</acronym>
  <official_title>Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized double-blinded placebo-controlled phase 2 study is to determine&#xD;
      efficacy of preoperative treatment with interferon-alfa2a in patients with pMMR colon cancer&#xD;
      on perioperative immune suppression and infiltration of lymphocytes in the primary tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded placebo-controlled phase 2 study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-analysis of lymphocytic subpopulations in blood</measure>
    <time_frame>Change between day of surgery (day 7-14 after first treatment) and postoperative day 1.</time_frame>
    <description>Change in CD3, CD4, and CD8 between intervention and placebo groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T-cell infiltration in tumor</measure>
    <time_frame>Day of surgery (day 7-14 after first treatment)</time_frame>
    <description>Difference in CD3, CD4 and CD8 T-cell infiltration between intervention and placebo groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery (QoR-15)</measure>
    <time_frame>Third postoperative day and postoperative day 12-16</time_frame>
    <description>Difference in QoR-15 between intervention and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiplex gene assay - NanoString Pan Cancer 360 IO panel analysis in blood and resected tumor</measure>
    <time_frame>Day of first treatment (Day 0) and day of surgery (day 7-14 after first treatment)</time_frame>
    <description>Difference in gene expressions between intervention and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cfDNA analysis in blood</measure>
    <time_frame>Day of first treatment (Day 0), day of surgery (day 7-14 after first treatment), postoperative day 2, postoperative day 12-16, and postoperative day 28-32.</time_frame>
    <description>Difference between intervention and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiplex gene assay - NanoString Pan Cancer 360 IO panel analysis of tumor biopsy and resected specimen</measure>
    <time_frame>Day of standard endoscopic biopsy (Day -7-14 before treatment) and day of surgery (day 7-14 after first treatment)</time_frame>
    <description>Difference in gene expressions in tumor biopsies and resected specimen between intervention and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP and neutrophil/lymphocyte ratio</measure>
    <time_frame>Day of surgery (day 7-14 after first treatment)</time_frame>
    <description>Difference in CRP and neutrophil/lymphocyte ratio between intervention and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological and inflammatory cytokines and interleukins</measure>
    <time_frame>Day of surgery (day 7-14 after first treatment) and postoperative day 1.</time_frame>
    <description>Difference between intervention and placebo groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 45 mikrogram doses of interferon-alfa2a (Pegasys). Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two 1 ml doses of saline liquid. Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients above 18 years of age.&#xD;
&#xD;
          -  Patients diagnosed with pMMR colonic adenocarcinoma and scheduled for laparoscopic&#xD;
             hemicolectomy.&#xD;
&#xD;
          -  ASA class I-III (Classification of the American Society of Anesthesiology)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with childbearing potential without a negative pregnancy test before&#xD;
             initiating study drug and / or non-acceptance to the use of contraceptive methods *&#xD;
&#xD;
          -  ECOG score function&gt; / = 3&#xD;
&#xD;
          -  Current liver or renal disease.&#xD;
&#xD;
          -  Severe heart disease&#xD;
&#xD;
          -  Previous depression diagnosed by a psychiatrist or in treatment with antidepressant&#xD;
&#xD;
          -  Autoimmune disease.&#xD;
&#xD;
          -  Uncontrolled thyroid disease.&#xD;
&#xD;
          -  Patients who are or have recently (within 6 months) received treatment with&#xD;
             immunosuppressive agents other than corticosteroid treatment.&#xD;
&#xD;
          -  Epilepsy and / or other serious CNS disorders.&#xD;
&#xD;
          -  Patients that have undergone major surgery within one month before planned colon&#xD;
             resection.&#xD;
&#xD;
          -  Known hypersensitivity to recombinant interferon or auxiliary products of Pegasys®.&#xD;
&#xD;
               -  Spiral, pill, implant, transdermal patch, vaginal ring or depot injection.&#xD;
                  Sterile / infertile subjects are exempt from the use of contraception. To be&#xD;
                  considered sterile or infertile must generally be surgical sterilization&#xD;
                  (vasectomy, bilateral tubectomy, hysterectomy or ovariectomy) or be&#xD;
                  postmenopausal, defined as absent menstruation for at least 12 months prior to&#xD;
                  study enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ismail Gögenur, MD, Professor</last_name>
    <phone>26356426</phone>
    <phone_ext>0045</phone_ext>
    <email>igo@regsj.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikail Gögenur, MD</last_name>
    <phone>31429929</phone>
    <phone_ext>0045</phone_ext>
    <email>mgo@regsj.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Køge</city>
        <state>Zealand</state>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Dahlsgaard, Secretary</last_name>
      <phone>28738312</phone>
      <phone_ext>0045</phone_ext>
      <email>adha@regsj.dk</email>
    </contact>
    <investigator>
      <last_name>Ismail Gögenur, MD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikail Gögenur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

